Mycobacterial Diseases
Open Access

Emerging Drug-Resistant Mycobacteria

Berna Elya^{* *}Correspondence: Berna Elya, Department of Hospitalist Medicine, Cooper University Hospital, Camden, NJ 08103, USA, Email:

Author info »

Description

Mycobacterial infections, particularly Tuberculosis (TB), have long been a major global health concern. While significant progress has been made in controlling these infections, a new and concerning challenge has emerged-the rise of drug-resistant mycobacteria. In this article, we will investigate the growing threat posed by emerging drug-resistant mycobacteria, the factors following the pattern, and the urgent need for a coordinated global response.

The challenge of drug-resistant mycobacteria

Drug-resistant mycobacteria are strains of Mycobacterium tuberculosis (MTB), the bacterium responsible for TB, that have developed resistance to one or more of the antibiotics used to treat the disease. These resistant strains are classified into several categories:

Multi Drug-Resistant TB (MDR-TB): MDR-TB is resistant to two of the most potent first-line TB drugs, Isoniazid and Rifampicin.

Extensively Drug-Resistant TB (XDR-TB): XDR-TB is resistant not only to Isoniazid and Rifampicin but also to any Fluoroquinolone and at least one of the three injectable second- line drugs (Amikacin, Kanamycin, or Capreomycin).

Total Drug-Resistant TB (TDR-TB): While not officially recognized by all health organizations, TDR-TB refers to cases that are resistant to all known TB drugs.

The emergence of drug-resistant mycobacteria is a concern for several reasons:

Treatment complexity: Drug-resistant TB requires longer and more complex treatment regimens, often involving multiple drugs with more significant side effects. These regimens can last up to two years, making treatment adherence challenging.

Higher mortality: Drug-resistant TB is associated with higher mortality rates compared to drug-susceptible TB. Patients with MDR-TB and XDR-TB have limited treatment options and are more likely to experience treatment failure.

Transmission potential: Drug-resistant mycobacteria can be transmitted from person to person, posing a risk to public health. Controlling their spread requires strict infection control measures and contact tracing.

Factors driving drug resistance

Several factors contribute to the development and spread of drug-resistant mycobacteria:

Inadequate treatment: Incomplete or inadequate TB treatment is a primary catalyst of drug resistance. Patients who do not complete their full course of treatment or receive suboptimal drug regimens are at higher risk of developing resistance.

Mismanagement of TB cases: Delayed diagnosis, inappropriate drug prescribing, and lack of access to quality healthcare can lead to the mismanagement of TB cases, increasing the risk of resistance.

Lack of access to diagnostics: Timely diagnosis of drug-resistant TB is essential, but many regions lack access to rapid and accurate diagnostic tools, resulting in delayed treatment initiation.

Cross-resistance: Some drug-resistant TB strains develop cross- resistance, meaning that resistance to one drug can lead to resistance to others, limiting treatment options.

Immune compromised individuals: People with compromised immune systems, such as those living with HIV/AIDS, are at greater risk of developing drug-resistant TB.

The global impact of drug-resistant mycobacteria

The global impact of drug-resistant mycobacteria is significant and far-reaching:

Increased healthcare costs: Treating drug-resistant TB is more costly and resource-intensive than treating drug-susceptible TB, placing a burden on healthcare systems.

Economic consequences: Drug-resistant TB can have economic repercussions, as affected individuals are often unable to work, leading to lost productivity.

Threat to progress: The emergence of drug-resistant mycobacteria threatens to undermine the progress made in TB control efforts, particularly in regions with high TB burden.

Global transmission: Drug-resistant TB strains do not respect borders and can be transmitted globally, making it a concern for international public health.

A global response of drug-resistant mycobacteria

Addressing the growing threat of drug-resistant mycobacteria requires a coordinated global response:

Improved diagnostics: Widespread access to rapid and accurate diagnostic tools is essential for early detection and prompt initiation of appropriate treatment.

Strengthen healthcare systems: Strengthening healthcare systems to ensure that all TB cases are properly managed and treated is important in preventing the development of drug resistance.

Antimicrobial stewardship: Implementing antimicrobial programs to prevent inappropriate antibiotic use can slow the emergence of drug resistance.

Research and development: Continued research into new drugs, vaccines, and diagnostic tools for TB is vital. The development of new drugs, particularly those targeting drug- resistant TB, is a priority.

Infection control: Strict infection control measures in healthcare settings and the community are essential to prevent the spread of drug-resistant mycobacteria.

Global collaboration: Collaboration between countries and international organizations is necessary to address the global nature of drug-resistant TB.

Conclusion

The emergence of drug-resistant mycobacteria, particularly MDR-TB and XDR-TB, represents a growing threat to global public health. These drug-resistant strains are associated with higher mortality rates, increased healthcare costs, and the potential for global transmission.

Addressing this challenge requires a multi-pronged approach, including improved diagnostics, strengthened healthcare systems, antimicrobial stewardship, research and development, and global collaboration. Failure to take decisive action could undo the progress made in TB control efforts and result in a resurgence of this ancient and formidable disease. It is imperative that the international community prioritizes efforts to combat drug-resistant mycobacteria and prevent their further spread.